Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells

Current Cancer Drug Targets

Volumn 14, Issue 4, 2014, Pages 407-417

  Wang, Rui ^a   Cheng, Long ^a   Xia, Jun ^a   Wang, Zishu ^a   Wu, Qiong ^a   Wang, Zhiwei ^b  

^a BENGBU MEDICAL COLLEGE   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Chemoresistance; EMT; Gemcitabine; HIF 1 ; Pancreatic cancer

Indexed keywords

GEMCITABINE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; ANTINEOPLASTIC ANTIMETABOLITE; BIOLOGICAL MARKER; DEOXYCYTIDINE; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SMALL INTERFERING RNA; TUMOR PROTEIN;

ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MTT ASSAY; PANCREAS CANCER; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING; AGONISTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84903749390     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140226114015     Document Type: Article

References (48)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11-30.
2. Werner, J.; Combs, S. E.; Springfeld, C.; Hartwig, W.; Hackert, T.; Buchler, M. W. Advanced-stage pancreatic cancer: therapy options. Nat. Rev. Clin. Oncol. 2013, 10, 323-333.
3. Paulson, A. S.; Tran Cao, H. S.; Tempero, M. A.; Lowy, A. M. Therapeutic advances in pancreatic cancer. Gastroenterology 2013, 144, 1316-1326.
4. Cao, H.; Le, D.; Yang, L. X. Current status in chemotherapy for advanced pancreatic adenocarcinoma. Anticancer Res. 2013, 33, 1785-1791.
5. Sun, C.; Ansari, D.; Andersson, R.; Wu, D. Q. Does gemcitabinebased combination therapy improve the prognosis of unresectable pancreatic cancer? World J. Gastroenterol. 2012, 18, 4944-4958.
6. Arumugam, T.; Ramachandran, V.; Fournier, K. F.; Wang, H.; Marquis, L.; Abbruzzese, J. L.; Gallick, G. E.; Logsdon, C. D.; McConkey, D. J.; Choi, W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69, 5820-5828.
7. Li, Y.; VandenBoom, T. G., 2nd; Kong, D.; Wang, Z.; Ali, S.; Philip, P. A.; Sarkar, F. H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69, 6704-6712.
8. Shah, A. N.; Summy, J. M.; Zhang, J.; Park, S. I.; Parikh, N. U.; Gallick, G. E. Development and characterization of gemcitabineresistant pancreatic tumor cells. Ann. Surg. Oncol. 2007, 14, 3629-3637.
9. Wang, Z.; Li, Y.; Kong, D.; Banerjee, S.; Ahmad, A.; Azmi, A. S.; Ali, S.; Abbruzzese, J. L.; Gallick, G. E.; Sarkar, F. H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabineresistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69, 2400-2407.
10. Keith, B.; Johnson, R. S.; Simon, M. C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12, 9-22.
11. Denko, N. C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 2008, 8, 705-713.
12. Majmundar, A. J.; Wong, W. J.; Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 2010, 40, 294-309.
13. Rankin, E. B.; Giaccia, A. J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008, 15, 678-685.
14. Cannito, S.; Novo, E.; Compagnone, A.; Valfre di Bonzo, L.; Busletta, C.; Zamara, E.; Paternostro, C.; Povero, D.; Bandino, A.; Bozzo, F.; Cravanzola, C.; Bravoco, V.; Colombatto, S.; Parola, M. Redox mechanisms switch on hypoxia-dependent epithelialmesenchymal transition in cancer cells. Carcinogenesis 2008, 29, 2267-2278.
15. Cheng, Z. X.; Sun, B.; Wang, S. J.; Gao, Y.; Zhang, Y. M.; Zhou, H. X.; Jia, G.; Wang, Y. W.; Kong, R.; Pan, S. H.; Xue, D. B.; Jiang, H. C.; Bai, X. W. Nuclear factor-kappaB-dependent epithelial to mesenchymal transition induced by HIF-1alpha activation in pancreatic cancer cells under hypoxic conditions. PLoS One 2011, 6, e23752.
16. Kasuya, K.; Tsuchida, A.; Nagakawa, Y.; Suzuki, M.; Abe, Y.; Itoi, T.; Serizawa, H.; Nagao, T.; Shimazu, M.; Aoki, T. Hypoxiainducible factor-1alpha expression and gemcitabine chemotherapy for pancreatic cancer. Oncol. Rep. 2011, 26, 1399-1406.
17. Wang, Z.; Ahmad, A.; Banerjee, S.; Azmi, A.; Kong, D.; Li, Y.; Sarkar, F. H. FoxM1 is a novel target of a natural agent in pancreatic cancer. Pharm. Res. 2010, 27, 1159-1168.
18. Azmi, A. S.; Aboukameel, A.; Banerjee, S.; Wang, Z.; Mohammad, M.; Wu, J.; Wang, S.; Yang, D.; Philip, P. A.; Sarkar, F. H.; Mohammad, R. M. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur. J. Cancer 2010, 46, 1122-1131.
19. Deer, E. L.; Gonzalez-Hernandez, J.; Coursen, J. D.; Shea, J. E.; Ngatia, J.; Scaife, C. L.; Firpo, M. A.; Mulvihill, S. J. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010, 39, 425-435.
20. Monti, P.; Marchesi, F.; Reni, M.; Mercalli, A.; Sordi, V.; Zerbi, A.; Balzano, G.; Di Carlo, V.; Allavena, P.; Piemonti, L. A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch. 2004, 445, 236-247.
21. Xia, J.; Duan, Q.; Ahmad, A.; Bao, B.; Banerjee, S.; Shi, Y.; Ma, J.; Geng, J.; Chen, Z.; Rahman, K. M.; Miele, L.; Sarkar, F. H.; Wang, Z. Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Curr. Drug Targets 2012, 13, 1750-1756.
22. Kong, D.; Wang, Z.; Sarkar, S. H.; Li, Y.; Banerjee, S.; Saliganan, A.; Kim, H. R.; Cher, M. L.; Sarkar, F. H. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008, 26, 1425-1435.
23. Wang, Z.; Kong, D.; Banerjee, S.; Li, Y.; Adsay, N. V.; Abbruzzese, J.; Sarkar, F. H. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res. 2007, 67, 11377-11385.
24. Wang, Z.; Banerjee, S.; Li, Y.; Rahman, K. M.; Zhang, Y.; Sarkar, F. H. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006, 66, 2778-2784.
25. Elnaggar, M.; Giovannetti, E.; Peters, G. J. Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Curr. Pharm. Des. 2012, 18, 2811-2829.
26. Ying, J. E.; Zhu, L. M.; Liu, B. X. Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J. Gastroenterol. 2012, 18, 736-745.
27. Du, Z.; Qin, R.; Wei, C.; Wang, M.; Shi, C.; Tian, R.; Peng, C. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Dig. Dis. Sci. 2011, 56, 741-750.
28. Kikuta, K.; Masamune, A.; Watanabe, T.; Ariga, H.; Itoh, H.; Hamada, S.; Satoh, K.; Egawa, S.; Unno, M.; Shimosegawa, T. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2010, 403, 380-384.
29. Gungor, C.; Zander, H.; Effenberger, K. E.; Vashist, Y. K.; Kalinina, T.; Izbicki, J. R.; Yekebas, E.; Bockhorn, M. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res. 2011, 71, 5009-5019.
30. Wang, Z.; Li, Y.; Ahmad, A.; Azmi, A. S.; Kong, D.; Banerjee, S.; Sarkar, F. H. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist. Updat. 2010, 13, 109-118.
31. Cordelier, P.; Torrisani, J. MicroRNAs in pancreatic cancer: potential interests as biomarkers and therapeutic tools. MicroRNAs in cancer translational research. 2011, Springer, 287-307.
32. Li, Y.; Li, W.; Yang, Y.; Lu, Y.; He, C.; Hu, G.; Liu, H.; Chen, J.; He, J.; Yu, H. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res. 2009, 1286, 13-18.
33. Moriyama, T.; Ohuchida, K.; Mizumoto, K.; Yu, J.; Sato, N.; Nabae, T.; Takahata, S.; Toma, H.; Nagai, E.; Tanaka, M. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol. Cancer Ther. 2009, 8, 1067-1074.
34. Giovannetti, E.; Funel, N.; Peters, G. J.; Del Chiaro, M.; Erozenci, L. A.; Vasile, E.; Leon, L. G.; Pollina, L. E.; Groen, A.; Falcone, A.; Danesi, R.; Campani, D.; Verheul, H. M.; Boggi, U. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010, 70, 4528-4538.
35. Hwang, J. H.; Voortman, J.; Giovannetti, E.; Steinberg, S. M.; Leon, L. G.; Kim, Y. T.; Funel, N.; Park, J. K.; Kim, M. A.; Kang, G. H.; Kim, S. W.; Del Chiaro, M.; Peters, G. J.; Giaccone, G. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010, 5, e10630.
36. Mace, T. A.; Collins, A. L.; Wojcik, S. E.; Croce, C. M.; Lesinski, G. B.; Bloomston, M. Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells. J. Surg. Res. 2013, 184, 855-860.
37. Bao, B.; Ali, S.; Ahmad, A.; Azmi, A. S.; Li, Y.; Banerjee, S.; Kong, D.; Sethi, S.; Aboukameel, A.; Padhye, S. B.; Sarkar, F. H. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One 2012, 7, e50165.
38. Mani, S. A.; Guo, W.; Liao, M. J.; Eaton, E. N.; Ayyanan, A.; Zhou, A. Y.; Brooks, M.; Reinhard, F.; Zhang, C. C.; Shipitsin, M.; Campbell, L. L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R. A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715.
39. Hong, S. P.; Wen, J.; Bang, S.; Park, S.; Song, S. Y. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer. 2009, 125, 2323-2331.
40. Van den Broeck, A.; Gremeaux, L.; Topal, B.; Vankelecom, H. Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. BMC Cancer 2012, 12, 354.
41. Quint, K.; Tonigold, M.; Di Fazio, P.; Montalbano, R.; Lingelbach, S.; Ruckert, F.; Alinger, B.; Ocker, M.; Neureiter, D. Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. Int. J. Oncol. 2012, 41, 2093-2102.
42. Bao, B.; Ahmad, A.; Kong, D.; Ali, S.; Azmi, A. S.; Li, Y.; Banerjee, S.; Padhye, S.; Sarkar, F. H. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One 2012, 7, e43726.
43. Singh-Gupta, V.; Banerjee, S.; Yunker, C. K.; Rakowski, J. T.; Joiner, M. C.; Konski, A. A.; Sarkar, F. H.; Hillman, G. G. B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer. Cancer Lett. 2012, 318, 86-92.
44. Singh-Gupta, V.; Joiner, M. C.; Runyan, L.; Yunker, C. K.; Sarkar, F. H.; Miller, S.; Gadgeel, S. M.; Konski, A. A.; Hillman, G. G. Soy isoflavones augment radiation effect by inhibiting APE1/Ref-1 DNA repair activity in non-small cell lung cancer. J. Thorac Oncol. 2011, 6, 688-698.
45. Qian, B.; Nag, S. A.; Su, Y.; Voruganti, S.; Qin, J. J.; Zhang, R.; Cho, W. C. miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents. Curr. Cancer Drug Targets 2013, 13, 519-541.
46. Melkamu, T.; Zhang, X.; Tan, J.; Zeng, Y.; Kassie, F. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 2010, 31, 252-258.
47. Ali, S.; Ahmad, A.; Banerjee, S.; Padhye, S.; Dominiak, K.; Schaffert, J. M.; Wang, Z.; Philip, P. A.; Sarkar, F. H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70, 3606-3617.
48. Paik, W. H.; Kim, H. R.; Park, J. K.; Song, B. J.; Lee, S. H.; Hwang, J. H. Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol. Anticancer Res. 2013, 33, 1473-1481.